Soliqua / Lyxumia

At a Glance
Therapeutic Area:
Type-2 Diabetes
Approved Applications:
Soliqua™ is an injectable prescription medicine that contains two diabetes medicines, insulin glargine and lixisenatide, that may improve blood sugar (glucose) control in adults with type-2 diabetes, when used with diet and exercise in people who are not controlled with long-acting (basal) insulin (less than 60 units daily) or lixisenatide.
Applications In Development:
N/A
Acquisition Date:
Undisclosed
Royalty Seller:
Undisclosed
Marketer:
 
 

Soliqua
Lyxumia
"Sanofi continues to be a pioneer in developing diabetes therapies and in bringing forward new treatment options for the approximately 50 percent of patients whose blood sugar levels remain uncontrolled on daily basal insulin. Soliqua 100/33 is an alternate new approach that can help adults living with type-2 diabetes uncontrolled on basal insulin or lixisenatide to reach their treatment goal"

Elias Zerhouni, MD, President, Global R&D, Sanofi

Latest News

 
© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.